Az imatinibkezelés hatása gastrointestinalis stroma eredetu daganatokban

Translated title of the contribution: Effect of imatinib treatment of gastrointestinal stromal tumours

Sándor Eckhardt, Zsuzsanna Pépai, György Bodoky, József Horti, Karin Tamás, Tünde Nagy, Zsolt Orosz, Zoltán Sépi, Mária Godény, Klára Jakab, Olga Ésik, Lajos Trón, István Besznyák

Research output: Contribution to journalArticle

Abstract

Introduction: advanced malignant gastrointestinal stromal tumours are practically resistant to further radio- or chemotherapy. These tumours are characterized by the presence of C-KIT (a transmembrane tyrosin kinase) mutation which can be specified by CD117 expression. Imatinib (2-fenilaminopirimidine) is a selective inhibitor of the mutated C-KIT. Aim: The purpose of our study was to determine the potential antitumour effect of imatinib in patients with gastrointestinal stroma tumour patients. Materials and methods: an open, non-randomized trial was performed involving 38 patients each of which had recidive/metastatic disease associated with CD117 positivity. Consecutively daily doses of 400-600 mg imatinib was administered orally to the patients. The evaluation was carried out on 37 patients in a form of an interim analysis. Results: after a 3-18 months observation period 1 complete, 19 partial remissions and 10 static diseases could be registered (78%), in association of only grade 1-2 toxicity. Conclusions: the imatinib treatment improved the quality of life of the patients with gastrointestinal stroma tumour and their life expectancy became considerably prolonged. Further follow-up of the patients as well as design of a prospective, randomized trial on a larger patient material is urgently needed.

Original languageHungarian
Pages (from-to)929-934
Number of pages6
JournalOrvosi hetilap
Volume146
Issue number18 SUPPL.1
Publication statusPublished - Dec 1 2005

    Fingerprint

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Eckhardt, S., Pépai, Z., Bodoky, G., Horti, J., Tamás, K., Nagy, T., Orosz, Z., Sépi, Z., Godény, M., Jakab, K., Ésik, O., Trón, L., & Besznyák, I. (2005). Az imatinibkezelés hatása gastrointestinalis stroma eredetu daganatokban. Orvosi hetilap, 146(18 SUPPL.1), 929-934.